We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Magnetic Microneedle Array Robots to Revolutionize Tissue Slicing and Cultivation

By LabMedica International staff writers
Posted on 01 Aug 2024

The cultivation of patient-derived tissues in vitro is essential for accurate diagnosis, targeted treatments, and advancements in tissue engineering. More...

However, traditional methods of tissue slicing and cultivation often do not meet the clinical needs. Addressing this gap, a groundbreaking method has been developed that incorporates a controllable histotomy technique using hierarchical magnetic microneedle array robots. This innovation not only enhances tissue analysis capabilities but also paves the way for personalized medicine and the development of more effective therapies. As this technology evolves, it is anticipated to significantly impact biomedical research and clinical practices.

A team from Nanjing Drum Tower Hospital (Nanjing, China) has pioneered this innovative tissue slicing and cultivation method that promises to transform how primary tissues are managed in medical settings. Described in a research article published in Engineering, the method employs a three-dimensional printed slicing device with a mortise-tenon structure and a pagoda-shaped microneedle array scaffold loaded with magnetic particles. The multilayered structure of the microneedles ensures stable fixation of tissue samples during slicing, preventing slippage. Additionally, the encapsulated magnetic microneedle fragments convert tissue sections into biohybrid microrobots that can be magnetically manipulated for separation, transport, and dynamic culture.

This method was tested with primary pancreatic cancer tissues, which were segmented into small sections and cultured in multilayered microfluidic chips for comprehensive drug screening. The outcomes are promising for clinical application, marking a substantial advancement in the field of precision medicine. The research article also outlines potential enhancements, such as automating the tissue sectioning process and increasing the throughput of the microtomy device. Going forward, the researchers see potential applications of this technology extending beyond cancer to include various types of patient-derived tissues, potentially revolutionizing long-term tissue cultivation and monitoring.

“The development of this controllable histotomy technique marks a significant advancement in the field of tissue engineering and drug screening,” said Jiaming Wu, the editor of Engineering. “By leveraging the capabilities of magnetic microneedle array robots, researchers have been able to create a more efficient and precise method for tissue manipulation and analysis.”

Related Links:
Nanjing Drum Tower Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.